NCT00082836View on ClinicalTrials.gov

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2007

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Trial Locations (1)

10021

Memorial Sloan - Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00082836 - Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma | Biotech Hunter | Biotech Hunter